Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
So argued researchers behind a study that switched people from triple-antiretroviral regimens to Tivicay monotherapy.
Researchers presented 100-week data on a trial of the antiretroviral (ARV) regimen at the international AIDS conference.
A large ongoing study in Botswana has found that about 1 in 150 babies exposed to Tivicay at conception developed such birth defects.
Tivicay (dolutegravir) is a next-generation integrase inhibitor.
The integrase inhibitor is included in the single-tablet HIV regimens Triumeq and Juluca.
After a gay man tested HIV positive, a test of his hair indicated he’d adhered well to PrEP—but did he contract a drug-resistant strain?
Juluca is a single-tablet regimen for HIV.
ViiV alleges that the bictegravir component of the tablet infringes on its own patent for Tivicay (dolutegravir).
The single-tablet regimen contains ViiV’s Tivicay (dolutegravir) and Janssen’s Edurant (rilpivirine).
The combo of Tivicay (dolutegravir) and Edurant (rilpivirine) showed comparable efficacy to three- and four-drug regimens in major trials.
Two large studies have found that the two-drug combination of Tivicay and Edurant works as well as standard three- or four-ARV regimens.
Two large trials switched participants from three- or four-drug combos to a regimen of Tivicay (dolutegravir) and Edurant (rilpivirine).
The trial will test a regimen of Tivicay (dolutegravir) plus Epivir (lamivudine) against Tivicay and Truvada (tenofovir/emtricitabine).
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.